ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade)
Source: SeekingAlpha
2026-03-29 09:00:04 ET
Read the full article on Seeking Alpha
For further details see:
ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade)
ADMA Biologics Inc
NASDAQ: ADMA
ADMA Trading
-1.95% G/L:
$9.06 Last:
3,203,316 Volume:
$9.035 Open:
ADMA Latest News
March 30, 2026 03:47:00 pm
ADMA Biologics, Inc. (ADMA) Crashes 16% Amid Scrutiny Over Skyrocketing Days Sales Outstanding That Short Seller Claims Points to Improper Channel Stuffing, Hagens Berman Investigating
March 30, 2026 12:10:00 am
Levi & Korsinsky Launches Fraud Investigation on Behalf of ADMA Biologics, Inc. (ADMA) Shareholders
ADMA Stock Data
$3,926,963,123
229,191,848
0.3%
148
N/A
Biotechnology & Life Sciences
Healthcare
US
Ramsey
